Subscribe

IMAGE IN CARDIOLOGY

DOI: 10.4244/EIJV11I5A118

Early hypoattenuated leaflet thickening and restricted leaflet motion of a Lotus transcatheter heart valve detected by 4D computed tomography angiography

Simon Schoechlin, MD; Philipp Ruile, MD; Franz-Josef Neumann, MD; Gregor Pache*, MD

An 85-year-old woman with severe aortic stenosis (AVA: 0.7 cm², mean gradient 56 mmHg) underwent transcatheter aortic valve implantation (TAVI) with a 25 mm Lotus™ transcatheter heart valve (Boston Scientific, Marlborough, MA, USA) via a femoral approach. Peri-interventionally, 600 mg clopidogrel, 400 mg aspirin and 5,000 IU heparin were administered. Post implantation the patient received dual antiplatelet therapy with aspirin 100 mg and clopidogrel 75 mg and heparin 7,500 IU bid.

To check the sizing and positioning of the valve, 4D computed tomography angiography (CTA) was carried out on day four which showed hypoattenuated thickening of the left prosthesis leaflet (Figure 1A-Figure 1C) and restricted leaflet motion (Figure 1A, Figure 1B, Moving image 1). Transthoracic echocardiography revealed a mean pressure gradient of 9 mmHg and, taking into account prosthesis-related shadowing, no signs of impaired leaflet motion.

The patient received modified antithrombotic therapy with clopidogrel/phenprocoumon (target INR 2.0 to 2.5). Follow-up CTA (day 74) showed almost complete resolution of the thickening, suggesting a thrombotic origin (Figure 1D-Figure 1F). However, we cannot rule out other potential causes which warrant further investigation.

Figure 1. 4D computed tomography angiography. 4D CTA on day 4 (A-C); 4D CTA on day 74 (D-F).

Conflict of interest statement

The authors have no conflicts of interest to declare.

Online data supplement

Moving image 1. 4D CTA video.

Supplementary data

To read the full content of this article, please download the PDF.

Moving image 1. 4D CTA video.

Volume 11 Number 5
Sep 22, 2015
Volume 11 Number 5
View full issue


Key metrics

Suggested by Cory

IMAGE IN CARDIOLOGY

10.4244/EIJV10I11A233 Mar 20, 2015
Pseudo early degeneration of a transcatheter aortic valve prosthesis due to thrombosis
de Brito Jr F et al
free

10.4244/EIJV10I2A44 Jun 20, 2014
Two cases of thrombotic stenosis in SAPIEN XT valves after transapical implantation
Leetmaa T et al
free

10.4244/EIJV7I1A28 May 17, 2011
Valve thrombosis after transcatheter heart valve implantation
Tay E et al
free

Viewpoint

10.4244/EIJ-D-24-00205 Jul 15, 2024
Subclinical leaflet thrombosis: should we be concerned?
Dangas G and Bay B
free

10.4244/EIJV13I15A281 Feb 2, 2018
Subclinical leaflet thrombosis – a concern, but also an issue?
Søndergaard L
free

AORTIC VALVE INTERVENTIONS

10.4244/EIJV12SYA7 Sep 18, 2016
Leaflet motion abnormality after TAVI: genuine threat or much ado about nothing?
Chakravarty T et al
free

10.4244/EIJV15I7A102 Sep 20, 2019
Antithrombotic therapy after TAVI: where are we going?
Wilkins B et al
free
Trending articles
69.996

10.4244/EIJV13I12A217 Dec 8, 2017
Swimming against the tide: insights from the ORBITA trial
Al-Lamee R and Francis D
free
59.65

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
57.6

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
38.75

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
15.85

State-of-the-Art

10.4244/EIJ-D-23-01050 Jul 15, 2024
Durability of transcatheter aortic valve implantation
Ternacle J et al
free
Chat with Cory
Hello , I'm Cory and I will do my best to answer your questions about this article. Please remember that this is an experimental feature, and that I'm still learning.
What was the rationale for modifying the patient's antithrombotic therapy?
What was the mean pressure gradient across the prosthetic valve on echocardiography?
What was the target INR range for the patient's modified antithrombotic therapy?
What were the key findings on the follow-up 4D CTA compared to the initial study?
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved